Thinking About a Booster Shot?

Waning Immunity after the BNT162b2 Vaccine in Israel –

The graph shows increases in the numbers of daily severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and new cases of severe coronavirus disease 2019 (Covid-19), on different scales, during the delta variant wave among persons who had received two doses of vaccine.

Waning Immunity after the BNT162b2 Vaccine in Israel –

It may be real nerdy but I like to do my research.

Update on Severe Allergic or Anaphylactic Reactions to Initial Dose of Pfizer COVID-19 Vaccine — The Skeptical Cardiologist

A report from two CDC scientists was published online today in JAMA Insights which describes in detail 21 cases of anaphylaxis that were reported to the US Vaccine Adverse Events Reporting System between December 14-23, 2020. This corresponds to a very low rate of 11.1 cases of anaphylaxis per million doses administered. 17 of these…

I continue to urge all my patients to get vaccinated as soon as possible. Benefits far outweigh the risk.

Update on Severe Allergic or Anaphylactic Reactions to Initial Dose of Pfizer COVID-19 Vaccine — The Skeptical Cardiologist

Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study

Vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis

Analysis evaluated 94 confirmed cases of COVID-19 in trial participants

Study enrolled 43,538 participants, with 42% having diverse backgrounds, and no serious safety concerns have been observed; Safety and additional efficacy data continue to be collected

Submission for Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) planned for soon after the required safety milestone is achieved, which is currently expected to occur in the third week of November

Clinical trial to continue through to final analysis at 164 confirmed cases in order to collect further data and characterize the vaccine candidate’s performance against other study endpoints

Press Release —

How Pfizer’s COVID-19 vaccine works: mRNA

“There was always a discussion: Is the spike protein the right target? Well, now we know it’s the right target,” Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, told STAT on Monday. “So, it’s not only immediate good news, it really is optimistic about what’s going to roll out in the next several months with the other vaccines.”

Four reasons for encouragement based on Pfizer’s Covid-19 vaccine results —